These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9093584

  • 21. Malignant hyperthermia.
    Rosenberg H, Davis M, James D, Pollock N, Stowell K.
    Orphanet J Rare Dis; 2007 Apr 24; 2():21. PubMed ID: 17456235
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Malignant hyperthermia in Austria. III. Anesthesia in susceptible patients].
    Mauritz W, Hackl W, Sporn P, Steinbereithner K.
    Anaesthesist; 1988 Aug 24; 37(8):522-8. PubMed ID: 3177878
    [Abstract] [Full Text] [Related]

  • 25. Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent.
    Shukry M, Guruli ZV, Ramadhyani U.
    Paediatr Anaesth; 2006 Apr 24; 16(4):462-5. PubMed ID: 16618304
    [Abstract] [Full Text] [Related]

  • 26. Anesthesia in malignant hyperthermia susceptible patients.
    Mauritz W, Hackl W, Winkler M, Sporn P, Steinbereithner K.
    Acta Anaesthesiol Belg; 1990 Apr 24; 41(2):87-94. PubMed ID: 1973553
    [Abstract] [Full Text] [Related]

  • 27. The severity of sevoflurane-induced malignant hyperthermia.
    Migita T, Mukaida K, Kobayashi M, Hamada H, Kawamoto M.
    Acta Anaesthesiol Scand; 2012 Mar 24; 56(3):351-6. PubMed ID: 22092278
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of malignant hyperthermia crisis during anesthesia].
    Amiel I, Nivoche Y.
    Ann Fr Anesth Reanim; 1989 Mar 24; 8(5):427-34. PubMed ID: 2697157
    [Abstract] [Full Text] [Related]

  • 29. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia.
    Dexter F, Epstein RH, Wachtel RE, Rosenberg H.
    Anesth Analg; 2013 Jan 24; 116(1):118-22. PubMed ID: 23223104
    [Abstract] [Full Text] [Related]

  • 30. Screening for malignant hyperthermia susceptibility.
    Anderson IL, Rawstron RE, Dunlop DJ.
    N Z Med J; 1980 Jun 11; 91(661):417-9. PubMed ID: 6930029
    [Abstract] [Full Text] [Related]

  • 31. Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review.
    Larach MG, Klumpner TT, Brandom BW, Vaughn MT, Belani KG, Herlich A, Kim TW, Limoncelli J, Riazi S, Sivak EL, Capacchione J, Mashman D, Kheterpal S, Kooij F, Wilczak J, Soto R, Berris J, Price Z, Lins S, Coles P, Harris JM, Cummings KC, Berman MF, Nanamori M, Adelman BT, Wedeven C, LaGorio J, McCormick PJ, Tom S, Aziz MF, Coffman T, Ellis TA, Molina S, Peterson W, Mackey SC, van Klei WA, Ginde AA, Biggs DA, Neuman MD, Craft RM, Pace NL, Paganelli WC, Durieux ME, Nair BJ, Wanderer JP, Miller SA, Helsten DL, Turnbull ZA, Schonberger RB, Multicenter Perioperative Outcomes Group.
    Anesthesiology; 2019 Jan 11; 130(1):41-54. PubMed ID: 30550426
    [Abstract] [Full Text] [Related]

  • 32. Malignant hyperthermia: a review.
    Johnson C, Edleman KJ.
    J Perinatol; 1992 Mar 11; 12(1):61-71. PubMed ID: 1560293
    [Abstract] [Full Text] [Related]

  • 33. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.
    Chan TY, Bulger TF, Stowell KM, Gillies RL, Langton EE, Street NE, Pollock NA.
    Anaesth Intensive Care; 2017 Nov 11; 45(6):707-713. PubMed ID: 29137581
    [Abstract] [Full Text] [Related]

  • 34. Current understanding of malignant hyperthermia: genesis, prevention, and treatment.
    Katz DN.
    CRNA; 1992 May 11; 3(2):54-63. PubMed ID: 1483145
    [Abstract] [Full Text] [Related]

  • 35. Repeated nonanesthetic malignant hyperthermia reactions in a child.
    Cummings T, Der T, Karsli C.
    Paediatr Anaesth; 2016 Dec 11; 26(12):1202-1203. PubMed ID: 27562486
    [Abstract] [Full Text] [Related]

  • 36. [Oral dantrolene in a parturient with myotonic dystrophy and susceptibility to malignant hyperthermia].
    Houvenaeghel M, Achilli-Cornesse E, Jullian-Papouin H, Martin-Meyssonier A, Manelli JC.
    Ann Fr Anesth Reanim; 1988 Dec 11; 7(5):408-11. PubMed ID: 3207229
    [Abstract] [Full Text] [Related]

  • 37. [Clinical features of malignant hyperthermia crisis].
    Cornet C, Moeller R, Laxenaire MC.
    Ann Fr Anesth Reanim; 1989 Dec 11; 8(5):435-43. PubMed ID: 2516711
    [Abstract] [Full Text] [Related]

  • 38. Successful Treatment Without Using Dantrolene Sodium on a Child Occurring Malignant Hyperthermia During Induction of General Anesthesia: A Case Report.
    Zheng Q, Liu N, Zeng Y, Chen Y, Zhang H, Su X, Zhuang J.
    J Craniofac Surg; 2024 Jun 01; 35(4):e351-e354. PubMed ID: 38829149
    [Abstract] [Full Text] [Related]

  • 39. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists.
    Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, McGrady E.
    Anaesthesia; 2021 May 01; 76(5):655-664. PubMed ID: 33399225
    [Abstract] [Full Text] [Related]

  • 40. Malignant Hyperthermia.
    Kaur H, Katyal N, Yelam A, Kumar K, Srivastava H, Govindarajan R.
    Mo Med; 2019 May 01; 116(2):154-159. PubMed ID: 31040503
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.